Amyloid Hypothesis

Clinical research is always delayed. Why? Patient recruitment is cited as the reason across the industry. This partly happens because the efforts put forth by Sponsors & CROs are often put together with less than ideal effort and forethought. Many people in charge of trials are o ... Show More

Patient retention is a thing that often gets overlooked. Yet, it can be one of the largest reasons contributing to you losing patients in your trials, your practice and in your care. Luckily there are some quick and easy fixes Heather and I share. 

Being persuasive is important in any facet of life. Everyone has to “sell” something every day. This means selling why you should be selected for that promotion, why your kid should listen to you, or why you should go eat somewhere over another suggested place. This applies to cl ... Show More

Send us Fan MailNinja Nerds,Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we explore Amyloidosis, a complex disorder characterized by the misfolding and deposition of insoluble amyloid fibrils in tissues. We break down the different subtypes, including AL ... Show More

<p>The human brain is mysterious and complicated. So much so, one might be tempted to argue that it only makes sense that we still don't have a cure for Alzheimer's disease, despite decades of research. But this isn't the whole story. We've partnered with Vox's <em>Unexplainable< ... Show More

This episode explores the current state of research on the multiple likely mechanisms of Alzheimer’s disease as well as promising treatments and diagnostics. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2309944. 

<pre class="syntaxhighlighter-pre" data-syntaxhighlighter-params= "brush: xml; gutter: false; theme: Midnight" data-theme= "Midnight">Do you know all there is to know beyond amyloid and tau in Alzheimer's disease? Credit available for this activity expires: 02/15/25 Earn Credit ... Show More

For decades, Alzheimer’s researchers have been stubbornly pursuing a single theory, but they’re starting to wonder: is this narrow focus the reason we still don’t have a cure? For more, go to http://vox.com/unexplainable It’s a great place to sign up for our newsletter, view show ... Show More

Review of the amyloidosis and its subtypes. 

<p>In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.<br /> <br /> <stron ... Show More

In this intimate finale of a two-part special, Dr. Sanjay Gupta decides to find out his own risk of Alzheimer’s disease. As he confronts his own genetic markers and lifestyle factors, Sanjay breaks down the science behind Alzheimer’s risk and explores what steps might slow down t ... Show More

<p>Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: <a href='https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-378'>https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-378</a></p> <p>Overview: Effective treatmen ... Show More